George Mason University has developed an AI-driven mobile app prototype for clinical documentation of bruises, aiming to aid survivors of violence.
Key Details
- 1George Mason University team created the Evidence-based AI Software for Injury Detection (EAS-ID) app, successfully completing Phase 1 prototype development.
- 2The app uses AI to capture and document bruises, guiding clinicians to produce images and records that meet clinical and legal standards.
- 3Initial funding of $4.85 million was received from an anonymous donor in March 2024.
- 4The app supports real-time guidance, image quality control, and standardized documentation, targeting frontline and forensic nursing professionals.
- 5AI training involves a large, diverse dataset, with a target of one million images collected; partnerships include Inova Health System and Adventist Healthcare.
- 6A crowdsourcing initiative will expand data beyond controlled clinical environments to improve real-world applicability.
Why It Matters
Standardized, AI-guided imaging for bruise documentation could enhance clinical and legal reliability for forensic nursing and clinicians, especially in sensitive cases like interpersonal violence. The project's scale and real-world data efforts signal potential for broader adoption of imaging AI in frontline care settings.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.